Follow-up to CEPI's $30 Million Funding Announcement in January

"Strengthening Infectious Disease Response Through Integrated Manufacturing Capabilities"

SK bioscience is strengthening its manufacturing collaboration with its subsidiary, IDT Biologika, as part of its ongoing Ebola vaccine development project with Merck (MSD) in the United States.


On March 23, SK bioscience announced that it has signed an agreement with IDT Biologika for contract development and manufacturing (CDMO) of drug product (DP) for its second-generation Zaire Ebola vaccine project, which is being carried out in partnership with MSD and the Hilleman Institute. This follows the decision by the Coalition for Epidemic Preparedness Innovations (CEPI) in January to provide approximately 30 million dollars in development funding for this project.


SK Bioscience Songdo Global R&PD Center exterior. SK Bioscience

SK Bioscience Songdo Global R&PD Center exterior. SK Bioscience

View original image

The Zaire Ebola virus is a high-risk infectious disease with a survival rate of only 50% upon infection. Recently, cases of re-emergence have been reported in some African regions, including the Democratic Republic of the Congo (DRC), raising concern within the international community. In particular, in areas with insufficient medical infrastructure, rapid response is difficult, making the stable supply of vaccines a critical challenge.


The development of the second-generation Zaire Ebola vaccine focuses on improving the manufacturing complexity and the burden of ultra-cold chain distribution associated with existing products. The key objectives are to increase manufacturing yields and enhance thermal stability, thereby improving the reliability and accessibility of vaccine supply. SK bioscience will produce the Ebola vaccine bulk substance in-house, while IDT Biologika will be responsible for the development and production of the finished product, leveraging its CDMO expertise, technical know-how, and state-of-the-art facilities.



Jinsun Park, Chief Operating Officer (COO) of SK bioscience, stated, "This agreement will serve as a foundation for strengthening the execution of global infectious disease response projects by linking the development and manufacturing capabilities of SK bioscience and IDT Biologika. We will continue to advance our integrated manufacturing platform to establish a stable system that meets international public health needs."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing